Drug reference

Cyclizine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 471, 472

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Nausea | Vomiting | Vertigo | Motion sickness | Labyrinthine disorders ▶BY MOUTH ▶Adult: 50 mg up to 3 times a day, for motion sickness, take 1–2 hours before departure ▶BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION ▶Adult: 50 mg 3 times a day Nausea and vomiting of known cause | Nausea and vomiting associated with vestibular disorders ▶BY MOUTH, OR BY INTRAVENOUS INJECTION ▶Child 1 month–5 years: 0.5–1 mg/kg up to 3 times a day (max. per dose 25 mg), intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure ▶Child 6–11 years: 25 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure ▶Child 12–17 years: 50 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure ▶BY RECTUM ▶Child 2–5 years: 12.5 mg up to 3 times a day ▶Child 6–11 years: 25 mg up to 3 times a day ▶Child 12–17 years: 50 mg up to 3 times a day Nervous system ▶BY CONTINUOUS INTRAVENOUS INFUSION, OR BY SUBCUTANEOUS INFUSION ▶Child 1–23 months: 3 mg/kg, dose to be given over 24 hours ▶Child 2–5 years: 50 mg, dose to be given over 24 hours ▶Child 6–11 years: 75 mg, dose to be given over 24 hours ▶Child 12–17 years: 150 mg, dose to be given over 24 hours Nausea and vomiting in palliative care ▶BY SUBCUTANEOUS INFUSION ▶Child 1–23 months: 3 mg/kg, dose to be given over 24 hours ▶Child 2–5 years: 50 mg, dose to be given over 24 hours ▶Child 6–11 years: 75 mg, dose to be given over 24 hours ▶Child 12–17 years: 150 mg, dose to be given over 24 hours ▶Adult: 150 mg, dose to be given over 24 hours ▶BY MOUTH ▶Child 1 month–5 years: 0.5–1 mg/kg up to 3 times a day (max. per dose 25 mg) ▶Child 6–11 years: 25 mg up to 3 times a day ▶Child 12–17 years: 50 mg up to 3 times a day ▶Adult: 50 mg up to 3 times a day ▶BY INTRAVENOUS INJECTION ▶Child 1 month–5 years: 0.5–1 mg/kg up to 3 times a day (max. per dose 25 mg), intravenous injection to be given over 3–5 minutes ▶Child 6–11 years: 25 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes ▶Child 12–17 years: 50 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes ▶BY CONTINUOUS INTRAVENOUS INFUSION ▶Child 1–23 months: 3 mg/kg, dose to be given over 24 hours ▶Child 2–5 years: 50 mg, dose to be given over 24 hours ▶Child 6–11 years: 75 mg, dose to be given over 24 hours ▶Child 12–17 years: 150 mg, dose to be given over 24 hours ▶BY RECTUM ▶Child 2–5 years: 12.5 mg up to 3 times a day ▶Child 6–11 years: 25 mg up to 3 times a day ▶Child 12–17 years: 50 mg up to 3 times a day l UNLICENSED USE ▶In children Tablets not licensed for use in children under 6 years. Injection not licensed for use in children.

PDF page 471

Cautions

Epilepsy. glaucoma (in children). may counteract haemodynamic beneﬁts of opioids. neuromuscular disorders—increased risk of transient paralysis with intravenous use. prostatic hypertrophy (in adults). pyloroduodenal obstruction. severe heart failure—may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure. susceptibility to angle-closure glaucoma (in adults). urinary retention

PDF page 471

Prescribing And Dispensing Information

Palliative care For further information on the use of cyclizine in palliative care, see www.medicinescomplete. com/#/content/palliative/antihistaminic-antimuscarinic-anti- emetics.

PDF page 472

Safety

Interactions

→Appendix 1: antihistamines, sedating

PDF page 471

Side Effects

GENERAL SIDE-EFFECTS ▶Rare or very rare Agitation (more common at high doses). angle closure glaucoma. depression ▶Frequency not known Abdominal pain. agranulocytosis. angioedema. anxiety. apnoea. appetite decreased. arrhythmias. asthenia. bronchospasm. constipation. diarrhoea. disorientation. dizziness. drowsiness. dry mouth. dry throat. euphoric mood. haemolytic anaemia. hallucinations. headache. hepatic disorders. hypertension. hypotension. increased gastric reﬂux. insomnia. leucopenia. movement disorders. muscle complaints. nasal dryness. nausea. oculogyric crisis. palpitations. paraesthesia. photosensitivity reaction. seizure. skin reactions. speech disorder. Nervous system thrombocytopenia. tinnitus. tremor. urinary retention. vision blurred. vomiting SPECIFIC SIDE-EFFECTS ▶With oral use Level of consciousness decreased ▶With parenteral use Chills. consciousness impaired. injection site necrosis. pain. paralysis. sensation of pressure. thrombophlebitis

PDF pages 471, 472

Pregnancy

Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

PDF page 472

Breast Feeding

No information available. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

PDF page 472

Hepatic Impairment

Manufacturer advises caution.

PDF page 472

Dose and formulations

Directions For Administration

For administration by mouth, tablets may be crushed. Mixing and compatibility for the use of syringe drivers in palliative care Cyclizine may precipitate at concentrations above 10 mg/mL or in the presence of sodium chloride 0.9% or as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.

PDF page 472

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, suppository Tablet CAUTIONARY AND ADVISORY LABELS 2 ▶Cyclizine (Non-proprietary) Cyclizine hydrochloride 50 mg Cyclizine 50mg tablets | 30 tablet p £2.95–£5.00 | 100 tablet p £12.15 DT = £7.04 Solution for injection ▶Cyclizine (Non-proprietary) Cyclizine lactate 50 mg per 1 ml Cyclizine 50mg/1ml solution for injection ampoules | 5 ampoule P £17.42 DT = £18.58 | 10 ampoule P £25.00–£37.16

PDF page 472

Clinical care

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); effects of alcohol enhanced.

PDF page 472

Dose text by age group

Adult

50 mg up to 3 times a day, for motion sickness,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

50 mg 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day, intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

12.5 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

150 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day, intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

12.5 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Cyclizine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 471, 472

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 471

Cautions

PDF page 471

Prescribing And Dispensing Information

Palliative care For further information on the use of cyclizine in palliative care, see www.medicinescomplete. com/#/content/palliative/antihistaminic-antimuscarinic-anti- emetics.

PDF page 472

Safety

Interactions

→Appendix 1: antihistamines, sedating

PDF page 471

Side Effects

PDF pages 471, 472

Pregnancy

PDF page 472

Breast Feeding

PDF page 472

Hepatic Impairment

Manufacturer advises caution.

PDF page 472

Dose and formulations

Directions For Administration

PDF page 472

Medicinal Forms

PDF page 472

Clinical care

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); effects of alcohol enhanced.

PDF page 472

Dose text by age group

Adult

50 mg up to 3 times a day, for motion sickness,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

50 mg 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day, intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

12.5 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

150 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Adult

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1 month–5 years

0.5–1 mg/kg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day, intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 1–23 months

3 mg/kg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

50 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

75 mg, dose to be given over 24 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

150 mg, dose to be given over

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 2–5 years

12.5 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 6–11 years

25 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Child 12–17 years

50 mg up to 3 times a day

First-line fragment. Read the complete Indications and Dose section above.

PDF page 471

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.